Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of OT-82 in Patients With Relapsed or Refractory Lymphoma

NCT03921879 is registered in ClinicalTrials.gov with Oncotartis, Inc. as lead sponsor.

NCT NCT03921879
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03921879 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of OT-82 in Patients With Relapsed or Refractory Lymphoma
Lead sponsor
Oncotartis, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
July 29, 2019
Completion date
June 30, 2021
Enrollment
50 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, lymphoma, b-cell, lymphoma, follicular, lymphoma, hodgkin, lymphoma, non-hodgkin, lymphoma, peripheral t-cell, lymphoma, t-cell